Item 8.01 Other Events. On September 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing that it has received notification from the U.S. Food and Drug Administration (the “FDA”) that the FDA had approved the Company’s supplemental New Drug Application for Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-Rh…
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
On
September 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing that it has received notification
from the U.S. Food and Drug Administration (the “FDA”) that the FDA had approved the Company’s supplemental New Drug
Application for Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy
using the BF-RhodoLED ® lamp series, for the treatment of superficial basal cell carcinoma in adults. A copy of the press
release is being furnished as Exhibit 99.1 attached to this Current Report on Form 8-K.
The
information contained in Item 8.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm
EX-99.1
2
ex99-1.htm
EX-99.1
Exhibit
99.1
Biofrontera
Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Ameluz
used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin
cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform
WOBURN,
Mass., September 14, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical
company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announced that the
U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED ® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults 1.
With
this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical
PDT in the United States indicated to treat both a pre-cancerous skin co…